News Boehringer buys Abexxa, bolstering its immuno-oncology pipel... Boehringer Ingelheim has agreed to buy US biotech Abexxa Biologics, its second acquisition in the cancer immunotherapy area in the space of a year.
R&D Reuters Pharma Europe 2024 – Peter Stenico Pioneering access to biosimilars is crucial for strengthening health equity by providing affordable, life-changing therapies to patients worldwide.
Digital Fixing clinical trial data management It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.